In vitro antimicrobial activity of defensins against ocular pathogens

J. S. Cullor, M. J. Mannis, C. J. Murphy, W. L. Smith, M. E. Selsted and T. W. Reid
Department of Clinical Pathology, School of Veterinary Medicine, University of California, Davis.

New approaches to antimicrobial therapy for ocular pathogens must overcome organisms that are resistant to current therapeutic modalities. This investigation examined the antimicrobial activity of novel antimicrobial neutrophil peptides (defensins NP-1 and NP-5) against isolates from clinical ocular microbial infections in humans and horses. The test panel of human clinical isolates included Candida albicans, an alpha-hemolytic Streptococcus, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Morganella morganii. The test panel of equine pathogens included three clinical isolates of P aeruginosa and two clinical isolates of Staphylococcus aureus. The equine isolates were chosen for their relative resistance to commonly employed antimicrobial therapy. The two defensins differed markedly in their bactericidal activity. Defensin NP-5, at a 50-micrograms/mL concentration, exhibited minimal bactericidal activity against the majority of isolates of the test panel. The inferior microbicidal activity of NP-5 is consistent with previously published results. However, at this concentration, NP-5 did exhibit appreciable bacteriostatic activity against human ocular pathogens M morganii (74%), alpha-hemolytic Streptococcus (57%), and P aeruginosa (93%) during the 2-hour incubation period. In contrast, defensin NP-1 at 10 micrograms/mL exerted potent microbicidal activity against all isolates, effecting a 2 to 3 log10 decrease in colony-forming units within a 60-minute incubation period. Under the assay conditions employed, these findings demonstrate: (1) two distinct mechanisms by which defensins exert their antimicrobial activity against microbial pathogens associated with clinical ocular disease in humans and horses, and (2) that rabbit defensin NP-1 is a potent antimicrobial agent against a wide array of ocular pathogens.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Novel Antimicrobial Peptide on the Ocular Surface Shows Decreased Expression in Inflammation and Infection
Abedin et al.
IOVS 2008;49:28-33.
ABSTRACT | FULL TEXT  

Ocular Pathogen or Commensal: A PCR-Based Study of Surface Bacterial Flora in Normal and Dry Eyes
Graham et al.
IOVS 2007;48:5616-5623.
ABSTRACT | FULL TEXT  

The in vitro activity of selected defensins against an isolate of Pseudomonas in the presence of human tears
McDermott et al.
Br. J. Ophthalmol. 2006;90:609-611.
ABSTRACT | FULL TEXT  

The Spectrum of Antimicrobial Peptide Expression at the Ocular Surface
McIntosh et al.
IOVS 2005;46:1379-1385.
ABSTRACT | FULL TEXT  

Regulation of Fungal Infection by a Combination of Amphotericin B and Peptide 2, a Lactoferrin Peptide That Activates Neutrophils
Okamoto et al.
CVI 2004;11:1111-1119.
ABSTRACT | FULL TEXT  

Phospholipase A2 Activity in Normal and Staphylococcus aureus-Infected Rabbit Eyes
Girgis et al.
IOVS 2003;44:197-202.
ABSTRACT | FULL TEXT  

Detection of Natural Peptide Antibiotics in Human Nasolacrimal Ducts
Paulsen et al.
IOVS 2001;42:2157-2163.
ABSTRACT | FULL TEXT  

Phospholipase A2 in Rabbit Tears: A Host Defense against Staphylococcus aureus
Moreau et al.
IOVS 2001;42:2347-2354.
ABSTRACT | FULL TEXT  

Fungal and Parasitic Infections of the Eye
Klotz et al.
Clin. Microbiol. Rev. 2000;13:662-685.
ABSTRACT | FULL TEXT